Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking passionate and experienced individual with strong statistical modeling background to be part of the Nonclinical Development and Clinical Pharmacology (NDCP) Organization. As a key member of the pharmacometrics group, you will: Develop and apply advanced statistical and machine learning methodologies to address complex scientific questions in PK/PD and exposure-response analysis. Design and implement model-based meta-analysis (MBMA) frameworks to integrate internal PKPD data and external data to inform clinical pharmacology strategies. Provide statistical and quantitative modeling support for key development decisions, including dose optimization and RP2D selection. Collaborate cross-functionally to ensure modeling approaches are scientifically rigorous, fit-for-purpose, and aligned with program objectives. Contribute to the continuous advancement of quantitative science capabilities, including method development, best practices, and adoption of innovative analytical approaches.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree